Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 631-639 of 639 results
J Control Release, 2005 • June 2, 2005
This report, single lumen and multiple lumen conduits capable of controlled, sustained release of neurotrophic factors were fabricated, and have potential application in nerve regeneration. These cond...
KEY FINDING: The porosity and mechanical properties of the constructs were regulated by the ratio of porogen to polymer microsphere.
British Journal of Pharmacology, 2009 • May 5, 2009
Traumatic brain injury (TBI) is a major public health problem lacking effective drug treatments. Progress in spinal cord injury research provides optimism for developing neuroregenerative therapies fo...
KEY FINDING: Axonal retraction bulbs are dynamic structures, not static markers of failed regeneration, suggesting they can be therapeutically targeted.
Clin Exp Pharmacol Physiol, 2010 • April 1, 2010
Glypican-1 is a major high-affinity ligand of the Slit proteins. Slit-2 and glypican-1 mRNA are upregulated and coexpressed in reactive astrocytes of injured adult brain, suggesting their involvement ...
KEY FINDING: Several potent inhibitors of glypican–Slit interactions were identified, including a low molecular weight periodate-oxidized heparin with no significant anticoagulant activity.
The Journal of Neuroscience, 2010 • January 13, 2010
The study identified daidzein, a soy isoflavone, as a potential therapeutic agent for CNS injuries due to its ability to induce Arg1 expression and promote axonal regeneration. Daidzein's mechanism of...
KEY FINDING: Daidzein was identified as a transcriptional inducer of Arg1 through a chemical screen of clinically approved drugs.
PLoS ONE, 2010 • March 16, 2010
This study demonstrates that RNA aptamers can be selected to bind the Nogo-66 receptor (NgR) and compete with myelin-derived inhibitors of axon regeneration for binding to the receptor. Neurite outgro...
KEY FINDING: RNA aptamers can be generated that bind with high affinity to NgR.
The Journal of Neuroscience, 2010 • March 31, 2010
This study addresses the challenge of limited axon regeneration after CNS injury due to myelin and glial scar inhibition. A chemical screen of a novel triazine library identified four compounds that o...
KEY FINDING: A chemical screen identified four novel triazine compounds (A05, C05, F05, and H08) that overcome myelin-mediated inhibition of neurite outgrowth.
Neurosci Lett, 2010 • September 6, 2010
This study demonstrates that GsMTx4, a mechanosensitive ion channel inhibitor, potentiates neurite outgrowth in PC12 cells when combined with NGF. The peptide's effect is dose-dependent and requires e...
KEY FINDING: GsMTx4, a peptide inhibitor of mechanosensitive ion channels, enhances neurite outgrowth from PC12 cells in the presence of NGF in a dose-dependent manner.
Exp Neurol, 2011 • October 1, 2011
This study investigates the effects of RhoA-inhibiting NSAIDs on oligodendrocyte survival and axonal myelination after spinal cord injury (SCI). The findings demonstrate that ibuprofen and indomethaci...
KEY FINDING: Ibuprofen and indomethacin reduced oligodendrocyte cell death in cultures exposed to TNF-α.
Tissue Engineering: Part A, 2011 • February 2, 2011
The study introduces a method for sustained drug delivery to the transected spinal cord using PLGA microspheres within OPF hydrogels. In vitro and in vivo experiments demonstrated the biological activ...
KEY FINDING: Encapsulating dbcAMP in microspheres prolonged its release and maintained its functionality.